Sort   by:  
 Page size 
ProteomicsTargeting Histone Modification Crosstalk as a Therapeutic Strategy for EZH2-aberrant Solid Tumors
Mutations or aberrant upregulation of the histone methyltransferase EZH2 occur frequently in human cancers yet EZH2-targeted therapies have only shown very limited clinical benefits in hematological malignancies. We report here that upon EZH2 inhibition, MLL1 interacts with p300/CBP complex that dir...
ORGANISM(S): Homo Sapiens 
2018-09-10 | PXD010842 |
ProteomicsDiscovery of Novel MLKL PROTAC Degrader for the Treatment of Hepatocellular Carcinoma via Promoting Parthanatos
Chen et al. discovered a highly potent and selective MLKL-targeted PROTAC C116 that effectively induces MLKL degradation and promotes parthanatos in HCC cells. More significantly, C116 was able to induce in vivo MLKL degradation and exerts anti-tumor activities in an orthotopic HCC tumor model, posi...
ORGANISM(S): Mus Musculus 
2025-10-14 | PXD069462 |
Sort   by:  
 Page size